Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
      • Neuroimmunology: To Sense and Protect
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Immunoprevention of Mammary Carcinoma in HER-2/neu Transgenic Mice Is IFN-γ and B Cell Dependent

Patrizia Nanni, Lorena Landuzzi, Giordano Nicoletti, Carla De Giovanni, Ilaria Rossi, Stefania Croci, Annalisa Astolfi, Manuela Iezzi, Emma Di Carlo, Piero Musiani, Guido Forni and Pier-Luigi Lollini
J Immunol August 15, 2004, 173 (4) 2288-2296; DOI: https://doi.org/10.4049/jimmunol.173.4.2288
Patrizia Nanni
*Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorena Landuzzi
*Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy;
† Istituti Ortopedici Rizzoli, Bologna, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giordano Nicoletti
*Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy;
† Istituti Ortopedici Rizzoli, Bologna, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carla De Giovanni
*Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ilaria Rossi
*Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefania Croci
*Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annalisa Astolfi
*Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuela Iezzi
‡ Aging Research Center, G. D’Annunzio University Foundation, Chieti, Italy; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma Di Carlo
‡ Aging Research Center, G. D’Annunzio University Foundation, Chieti, Italy; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Piero Musiani
‡ Aging Research Center, G. D’Annunzio University Foundation, Chieti, Italy; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guido Forni
§ Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pier-Luigi Lollini
*Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Prevention of mammary carcinogenesis in immunocompetent HER-2/neu transgenic mice (NeuT) and in transgenic mice deficient in IFN-γ production (NeuT-IFN-γ−/−) or in B cell immunity (NeuT-μMT). The results of NeuT-IFN-γ−/− mice were published previously (12 ) and are reported here for comparison. Groups of 8–12 mice received MSA, IL-12, or Neu/H-2q cells plus IL-12 as described in Materials and Methods. Tumor multiplicity was calculated as the cumulative number of incident tumors/total number of mice, and is shown as mean ± SEM. By the Mantel-Haenszel test, all tumor-free survival curves of mice vaccinated with Neu/H-2q cells plus IL-12 (red lines) were significantly different from one another (p < 0.01, at least). The survival curves of vaccinated NeuT and NeuT-μMT, but not that of NeuT-IFN-γ−/− mice, were significantly different (p < 0.01) from those of MSA-treated controls.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Immunohistochemistry of mammary tissue with invasive lobular carcinoma in untreated NeuT, vaccinated NeuT-IFN-γ−/−, and vaccinated NeuT-μMT mice, and with atypical hyperplasia in vaccinated NeuT mice. Immunostaining with anti-p185neu Ab shows that neoplastic cells of mammary carcinomas developed in untreated NeuT (A) and vaccinated NeuT-IFN-γ−/− (C) and NeuT-μMT (D) mice express p185neu in the cytoplasm and on the membrane. The expression of the p185neu is associated with a marked positivity of PCNA (E, G, H). The mammary glands of vaccinated NeuT mice were mainly composed of ductules lined by a single layer of epithelial cells without or with a faint p185neu expression mainly confined in the epithelial cell cytoplasm (B); the epithelial proliferation rate was low as assessed by PCNA immunostaining (F). A scanty microvessel network supplies the rare foci of mammary hyperplasia found in vaccinated NeuT mice (J). On the contrary, untreated NeuT (I) and vaccinated NeuT-IFN-γ−/− (K) mice developed well-vascularized carcinomas. A reduction in microvessel density was observed in vaccinated NeuT-μMT mice (L). A–L, ×400.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Ab response in vaccinated NeuT-μMT mice. A, Sera were collected from NeuT or NeuT-μMT mice after three monthly courses of vaccination and tested at 1/65 dilution against Neu/H-2q cells by indirect immunofluorescence followed by cytofluorometric analysis. Each point represents the mean fluorescence intensity (MFI) of one serum. B, Mean Ab levels induced by vaccination of NeuT-μMT mice compared with parental NeuT and μMT mice. Each bar represents the mean ± SEM of 6–23 individual mice scored as Ab-positive (MFI, >8). The percentage of Ab-positive mice in each vaccinated group is reported above the hatched bars.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Immunostaining with anti-B220 mAb of lymph node (A), spleen (B), Peyer patch (C), and intestinal lymphoid follicle (D) from NeuT-μMT mice. Positive B cells are scarce in lymph node and spleen, whereas they are well represented in intestinal lymphoid follicle and numerous in Peyer patch. A, ×200; B–D, ×400.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Immunoprevention of mammary carcinoma in NeuT-μMT mice is Ab dependent. Vaccinated NeuT-μMT mice shown in Fig. 1 were stratified according to Ab production in response to vaccination (see Fig. 3). Tumor-free survival curve of vaccinated, Ab-positive mice was significantly different from that of vaccinated, Ab-negative mice (p < 0.01 by the Mantel-Haenszel test).

  • FIGURE 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6.

    Whole mounts of inguinal mammary glands from one untreated (A) and two vaccinated NeuT-μMT mice, one Ab deficient (B), the other Ab proficient (C) at the age of 16 wk. The black oval in the center of each picture is the inguinal lymph node. In A and B numerous and large atypical hyperplastic foci (arrows) and a few established mammary carcinomas (arrowheads) were present, whereas a dramatic reduction in diffusion and dimension of hyperplastic foci and the absence of carcinoma were evident in C.

  • FIGURE 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 7.

    Release of IFN-γ by NeuT-μMT spleen cells. Spleens were obtained from untreated mice or from mice vaccinated with Neu/H-2q cells plus IL-12. IFN-γ release by spleen cells was assessed by ELISA after 6 days in vitro in the presence or absence of stimulator vaccine cells.

  • FIGURE 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 8.

    Ab response of vaccinated NeuT-μMT mice analyzed by immunoprecipitation and Western blot. A, Immunoreactivity of sera against native p185neu protein. Lysates of Neu/H-2q and Neuneg/H-2q cells (here referred to as Neu and Neuneg, respectively) were immunoprecipitated with pooled sera obtained from four vaccinated Ab-proficient (Ab+) or -deficient (Ab−) NeuT-μMT mice or from untreated NeuT-μMT mice (No vax). Immunoprecipitation with Ab4 anti-rat neu mAb (α-neu Ab) or with sera from vaccinated NeuT mice (NeuT/Vax) are shown for comparison. The C18 anti-p185neu rabbit Ab was used for Western blot. B, Immunoreactivity of mice sera against cryptic epitopes of p185neu protein. p185neu was immunoprecipitated with Ab4 mAb, denatured, and blotted using sera as above or C18 Ab (α-neu Ab). A HRP-linked goat anti-mouse IgG Ab was used for detection.

  • FIGURE 9.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 9.

    Subclasses of Abs induced by vaccination in NeuT, NeuT-IFN-γ−/−, and NeuT-μMT mice. The results of NeuT-IFN-γ−/− mice were previously published (12 ) and are reported here for comparison. Cytofluorometric analysis of serum binding to Neu/H-2q vaccine cells with secondary anti-mouse isotype Abs is reported. IgA and IgE Abs were absent from all sera (data not shown). Each bar represents the mean ± SEM of sera (1/65) from three to nine mice at the 17th week of age bled after the third course of vaccination.

  • FIGURE 10.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 10.

    Complement-mediated cytotoxicity (A) and ADCC (B) with sera of mice vaccinated with Neu/H-2q cells plus IL-12. Each point or bar represents the mean ± SEM of sera from three to four mice bled after the third course of vaccination (17 wk of age). ∗, Significantly different from NeuT mice (p < 0.01, Student’s t test).

  • FIGURE 11.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 11.

    Non-p185neu Abs elicited in NeuT-μMT mice by vaccination with Neu/H-2q cells plus IL-12. A, Cytofluorometric analysis of serum binding to vaccine cells or to a HER-2/neu transgenic, p185-negative mammary carcinoma clone (Neuneg/H-2q). Each bar represents the mean ± SEM of sera (1/65) from three to four mice at the 17th week of age bled after the third course of vaccination. B, Complement-mediated cytotoxicity against syngeneic lymph node cells (LNC) from NeuT (H-2d) mice or against MHC allogeneic H-2q LNC.

Tables

  • Figures
    • View popup
    Table I.

    B cell content of peripheral blood and lymphoid organs of NeuT and NeuT-μMT micea

    Lymphocyte OriginNeuTNeuT-μMT
    Ab-negativeAb-positive
    Peripheral blood50.0 ± 5.10.5 ± 0.21.4 ± 0.5
    Spleen45.5 ± 2.52.2 ± 0.35.0 ± 0.4b
    Mesenteric lymph node29.5 ± 3.30.5 ± 0.10.6 ± 0.2
    Inguinal lymph node26.2 ± 3.70.5 ± 0.20.6 ± 0.3
    Peyer patches60.7 ± 1.214.5 ± 1.525.2 ± 1.2b
    • a The percentage of B220-positive cells, evaluated by FACS analysis of gated lymphocytes, is expressed as the mean ± SEM of three to five mice per group.

    • b Significantly different from Ab-negative NeuT-μMT (p < 0.05, Student’s t test).

PreviousNext
Back to top

In this issue

The Journal of Immunology: 173 (4)
The Journal of Immunology
Vol. 173, Issue 4
15 Aug 2004
  • Table of Contents
  • About the Cover
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Immunoprevention of Mammary Carcinoma in HER-2/neu Transgenic Mice Is IFN-γ and B Cell Dependent
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Immunoprevention of Mammary Carcinoma in HER-2/neu Transgenic Mice Is IFN-γ and B Cell Dependent
Patrizia Nanni, Lorena Landuzzi, Giordano Nicoletti, Carla De Giovanni, Ilaria Rossi, Stefania Croci, Annalisa Astolfi, Manuela Iezzi, Emma Di Carlo, Piero Musiani, Guido Forni, Pier-Luigi Lollini
The Journal of Immunology August 15, 2004, 173 (4) 2288-2296; DOI: 10.4049/jimmunol.173.4.2288

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Immunoprevention of Mammary Carcinoma in HER-2/neu Transgenic Mice Is IFN-γ and B Cell Dependent
Patrizia Nanni, Lorena Landuzzi, Giordano Nicoletti, Carla De Giovanni, Ilaria Rossi, Stefania Croci, Annalisa Astolfi, Manuela Iezzi, Emma Di Carlo, Piero Musiani, Guido Forni, Pier-Luigi Lollini
The Journal of Immunology August 15, 2004, 173 (4) 2288-2296; DOI: 10.4049/jimmunol.173.4.2288
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Innate Immunity Together with Duration of Antigen Persistence Regulate Effector T Cell Induction
  • Regulatory Roles of IL-2 and IL-4 in H4/Inducible Costimulator Expression on Activated CD4+ T Cells During Th Cell Development
  • Induction of CD4+ T Cell Apoptosis as a Consequence of Impaired Cytoskeletal Rearrangement in UVB-Irradiated Dendritic Cells
Show more CELLULAR IMMUNOLOGY AND IMMUNE REGULATION

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2021 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606